stoxline Quote Chart Rank Option Currency Glossary
  
Axsome Therapeutics, Inc. (AXSM)
129.36  -6.32 (-4.66%)    11-20 16:00
Open: 133.81
High: 135.12
Volume: 811,750
  
Pre. Close: 135.68
Low: 128.13
Market Cap: 6,804(M)
Technical analysis
2026-11-20 4:42:41 PM
Short term     
Mid term     
Targets 6-month :  173.82 1-year :  192.47
Resists First :  148.82 Second :  164.78
Pivot price 137.13
Supports First :  123 Second :  102.33
MAs MA(5) :  134.39 MA(20) :  138.73
MA(100) :  192.57 MA(250) :  189.58
MACD MACD :  -7.8 Signal :  -8.8
%K %D K(14,3) :  35.3 D(3) :  41
RSI RSI(14): 32.8
52-week High :  260.19 Low :  123
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AXSM ] has closed above bottom band by 12.5%. Bollinger Bands are 31% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 135.5 - 136.25 136.25 - 136.86
Low: 125.87 - 126.91 126.91 - 127.75
Close: 127.83 - 129.37 129.37 - 130.62
Company Description

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.

Headline News

Sat, 21 Nov 2026
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Has Average Price Target of $266.21 - MarketBeat

Fri, 20 Nov 2026
Axsome Therapeutics, Inc. (AXSM) Stock Price, News, Quote & History - Yahoo! Finance Canada

Mon, 16 Nov 2026
Axsome Therapeutics Sees AUVELITY Prescription Surge After Alzheimer’s Agitation Launch - TradingView

Mon, 02 Nov 2026
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Tue, 27 Oct 2026
Axsome Therapeutics, Inc. (AXSM) - What Are Researchers Saying About This Stock? - MarketBeat

Mon, 05 Oct 2026
Why Baird Sees Growth Potential in Axsome Therapeutics, Inc. (AXSM) - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 53 (M)
Shares Float 45 (M)
Held by Insiders 15 (%)
Held by Institutions 74.4 (%)
Shares Short 3,110 (K)
Shares Short P.Month 3,140 (K)
Stock Financials
EPS -3.03
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2
Profit Margin -18.2 %
Operating Margin -5.2 %
Return on Assets (ttm) -13.7 %
Return on Equity (ttm) -175.6 %
Qtrly Rev. Growth 51.9 %
Gross Profit (p.s.) 15.33
Sales Per Share 16.45
EBITDA (p.s.) -2.91
Qtrly Earnings Growth 0 %
Operating Cash Flow -82 (M)
Levered Free Cash Flow -24 (M)
Stock Valuations
PE Ratio -42.7
PEG Ratio 0
Price to Book value 64.35
Price to Sales 7.86
Price to Cash Flow -83.22
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android